323 related articles for article (PubMed ID: 28432594)
21. Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells.
Falank C; Fairfield H; Reagan MR
Front Endocrinol (Lausanne); 2016; 7():67. PubMed ID: 27379019
[TBL] [Abstract][Full Text] [Related]
22. Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment.
Tang W; Xu J; Xu C
Cancer Lett; 2023 Mar; 556():216081. PubMed ID: 36739065
[TBL] [Abstract][Full Text] [Related]
23. From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.
Rossi M; Amodio N; Di Martino MT; Caracciolo D; Tagliaferri P; Tassone P
Curr Drug Targets; 2013 Sep; 14(10):1144-9. PubMed ID: 23834146
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches.
Rossi M; Amodio N; Di Martino MT; Tagliaferri P; Tassone P; Cho WC
Curr Pharm Biotechnol; 2014; 15(5):459-67. PubMed ID: 24846067
[TBL] [Abstract][Full Text] [Related]
25. [Role of Exosomal miRNA in Multiple Myeloma Progression and Its Possible Mechanism -Review].
Yang YZ; Zhang XY; Wan Q; Li J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):301-305. PubMed ID: 28245421
[TBL] [Abstract][Full Text] [Related]
26. Multiple myeloma: the bone marrow microenvironment and its relation to treatment.
Andrews SW; Kabrah S; May JE; Donaldson C; Morse HR
Br J Biomed Sci; 2013; 70(3):110-20. PubMed ID: 24273897
[TBL] [Abstract][Full Text] [Related]
27. Exosomes promote bone marrow angiogenesis in hematologic neoplasia: the role of hypoxia.
Ohyashiki JH; Umezu T; Ohyashiki K
Curr Opin Hematol; 2016 May; 23(3):268-73. PubMed ID: 26866730
[TBL] [Abstract][Full Text] [Related]
28. Organotypic culture of human bone marrow adipose tissue.
Uchihashi K; Aoki S; Shigematsu M; Kamochi N; Sonoda E; Soejima H; Fukudome K; Sugihara H; Hotokebuchi T; Toda S
Pathol Int; 2010 Apr; 60(4):259-67. PubMed ID: 20403027
[TBL] [Abstract][Full Text] [Related]
29. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
[TBL] [Abstract][Full Text] [Related]
30. Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.
Mahtouk K; Hose D; De Vos J; Moreaux J; Jourdan M; Rossi JF; Rème T; Goldschmidt H; Klein B
Clin Cancer Res; 2007 Dec; 13(24):7289-95. PubMed ID: 18094409
[TBL] [Abstract][Full Text] [Related]
31. Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma.
Soliman AM; Lin TS; Mahakkanukrauh P; Das S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066062
[TBL] [Abstract][Full Text] [Related]
32. The potential role of miRNAs in multiple myeloma therapy.
Caracciolo D; Montesano M; Altomare E; Scionti F; Di Martino MT; Tagliaferri P; Tassone P
Expert Rev Hematol; 2018 Oct; 11(10):793-803. PubMed ID: 30148649
[TBL] [Abstract][Full Text] [Related]
33. Multiple Myeloma Cell-Derived Exosomes: Implications on Tumorigenesis, Diagnosis, Prognosis and Therapeutic Strategies.
Allegra A; Di Gioacchino M; Tonacci A; Petrarca C; Musolino C; Gangemi S
Cells; 2021 Oct; 10(11):. PubMed ID: 34831088
[TBL] [Abstract][Full Text] [Related]
34. Characteristics, pathogenesis, and novel treatments for multiple myeloma.
San Miguel J
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S1-4. PubMed ID: 19791422
[TBL] [Abstract][Full Text] [Related]
35. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells.
Zheng P; Chen L; Yuan X; Luo Q; Liu Y; Xie G; Ma Y; Shen L
J Exp Clin Cancer Res; 2017 Apr; 36(1):53. PubMed ID: 28407783
[TBL] [Abstract][Full Text] [Related]
36. The role of circulating miRNAs in multiple myeloma.
Zhang J; Xiao X; Liu J
Sci China Life Sci; 2015 Dec; 58(12):1262-9. PubMed ID: 26607481
[TBL] [Abstract][Full Text] [Related]
37. The potential of miRNAs as biomarkers for multiple myeloma.
Rocci A; Hofmeister CC; Pichiorri F
Expert Rev Mol Diagn; 2014 Nov; 14(8):947-59. PubMed ID: 25098410
[TBL] [Abstract][Full Text] [Related]
38. Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance.
Ho M; Goh CY; Patel A; Staunton S; O'Connor R; Godeau M; Bianchi G
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e752-e768. PubMed ID: 32651110
[TBL] [Abstract][Full Text] [Related]
39. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
40. Role of exosome-associated microRNA in diagnostic and therapeutic applications to metabolic disorders.
Yao ZY; Chen WB; Shao SS; Ma SZ; Yang CB; Li MZ; Zhao JJ; Gao L
J Zhejiang Univ Sci B; 2018 Mar.; 19(3):183-198. PubMed ID: 29504312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
